News

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:FOLD). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd. The analyst notes that Amicus is well-positioned, but expectations have increased with the company’s progress, which are now largely priced into shares. The analyst downgraded the stock to Equal-weight from Overweigh

Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst

BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024. Spending by pharmaceutical and biotech companies dropped after pandemic-related overspending, and demand in China stayed weak. This led some Life Sciences companies to lower their already-conservative fiscal year revenue forecasts as the year progressed. For most of fiscal year 2024, Life Sciences company valuations remained higher than pre-COVID levels but declined after the U.S. elections. Looking ahead

Ciena's Strong 2025 Outlook Wins Analyst Confidence: AI Bandwidth And Optical Market Expansion In Focus

Ciena Corp (NYSE:CIEN) stock surged after BofA Securities upgraded it from Neutral to Buy and raised its price target from $70 to $95. Needham analyst Ryan Koontz maintained Ciena with a Buy and raised the price target from $80 to $95. Additionally, Northland Capital Markets, and Stifel raised their respective price targets on the stock. On Thursday, Ciena reported a fiscal fourth-quarter 2024 revenue decline of 0.5% to $1.12 billion, beating the analyst estimate of $1.10 billion. The adjusted E

General Mills To Gain Strength From Rebound In Pet Segment And Stabilizing Retail Growth, Analyst Upgrades Stock

BofA Securities analyst Peter T. Galbo upgraded General Mills, Inc. (NYSE:GIS) to Buy from Neutral, raising the price forecast to $80 from $78. The analyst suggests that General Mills is expected to return to organic sales growth at a faster and more sustainable rate compared to other center-store food peers. This growth will be driven by factors such as the re-acceleration in the Pet segment (specifically Blue Buffalo) and stabilization in North America Retail, as issues in the dough category a